logo
Dad of 2 Dies 10 Days After Brain Tumor Diagnosis, Holding His Family's Hands in Final Moments

Dad of 2 Dies 10 Days After Brain Tumor Diagnosis, Holding His Family's Hands in Final Moments

Yahoo03-06-2025
Glenn Colmer struggled with headaches but was told he likely needed new eyeglasses
The father of two had a sudden seizure and was diagnosed with a devastating brain tumor
His widow, Ali, says he kept reaching for her and their children's hands as he was dying, "squeezing tightly as if to say 'goodbye' "A father of two died less than a week after he was diagnosed with a brain tumor.
Glenn Colmer, 51, struggled for a year with headaches and body aches but was told to take pain medication. Some of his issues were chalked up to needing new eyeglasses, his wife, Ali, said, according to The Daily Mail. But that all changed when, on February 18, Glenn had a sudden, debilitating seizure at home in the English city of Southampton.
He'd just gotten up that morning and started to put his bathrobe on when he suddenly froze, Ali said. 'I asked if he was okay. He replied, 'No, I'm not,'' she said, sharing that he began shaking and gasping for air. 'I called an ambulance, staying calm for his sake, whispering words of reassurance until help arrived. The paramedics were quick to respond. Although the seizure had passed, Glenn was in visible pain, particularly in his arm, which had locked during the seizure. His eyes were vacant.'
'The trauma was immediate and life-altering,' said Ali, who explained that scans showed that he had a mass on his brain. Four days after he arrived at the hospital, on February 22, Ali, Glenn, and their two children, Grace, 19, and Joe, 16, were given the devastating news: The mass was a high-grade glioma brain tumor.
As the Mayo Clinic explains, it's a bleak diagnosis: 'There's no cure for glioblastoma. Treatments might slow cancer growth and reduce symptoms.'
The news, Ali says, was 'horrendous.'
'My world fell apart. The doctor tried to explain the scan. Glenn didn't want to look. He couldn't. He wasn't ready. His expression, once so full of life, humor, and warmth, was robbed from him, replaced with silence and vacancy,' she said.
When he was discharged and sent home for his final days, it was 'unbearable' for 'fit and healthy,' Glenn, who had worked as a Director of Curriculum for Sports and Protective Services at Itchen Sixth Form College, where he'd been a teacher for 20 years.
'His right side remained weak, and the vibrant man who once did every sport imaginable now needed help with the most basic tasks,' she said. 'He refused visitors. He didn't want people to see him this way.'
Glenn's pain escalated, and on February 25, he was rushed back to the hospital where doctors confirmed he had a brain hemorrhage.
'He kept reaching for my engagement ring and the children's hands, squeezing tightly as if to say 'goodbye.' He placed my hand on his heart, as if to say, 'Thank you.' Though no one had said it yet, I could see that Glenn was dying,' said Ali.
'Even as his body began to shut down and he was unable to speak, Glenn remained present. He kept reaching out, holding hands, squeezing gently,' said Ali.
Glenn died on February 28; a GoFundMe has been established to raise funds for a memorial bench in his honor.
'Glenn was more than his diagnosis. He was a mentor, a joker, a passionate teacher and friend,' said Ali who added that more than 500 people attended his funeral. 'He touched lives across the world. He made people feel seen, valued, and inspired.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
Read the original article on People
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'Modern Family' star opens up about heart disorder, getting pacemaker at 29
'Modern Family' star opens up about heart disorder, getting pacemaker at 29

USA Today

time28 minutes ago

  • USA Today

'Modern Family' star opens up about heart disorder, getting pacemaker at 29

Julie Bowen is opening up about the heart condition that led her to receive a pacemaker at age 29. In an appearance on the "Inside of You" podcast released on Tuesday, July 1, the "Modern Family" star, 55, discussed being diagnosed with sick sinus syndrome, a heart disorder that caused her to have a low heart rate. Bowen noted she was diagnosed soon after graduating college thanks to her sister, who was in medical school at the time. The actress always had a low heart rate, but when her sister listened to it with a stethoscope, she told Bowen, "You need to go to a cardiologist immediately." Bowen subsequently received her diagnosis and got a pacemaker under her armpit, right after shooting the pilot of her early 2000s NBC series, "Ed." "I was like, 'Oh my God. My life is over. This is so weird. I'm going to die.' I don't know what I thought it was," Bowen said. "I was 29 years old." 'Modern Family' star Julie Bowen clears up that viral hiker rescue story: 'I did nothing' The actress explained the condition would give her a feeling of lightheadedness − as if she had been holding her breath − whenever she was relaxed. Before receiving her pacemaker, which she has had replaced a few times since, doctors warned that this could result in Bowen passing out while behind the wheel of a car and causing an accident. What is sick sinus syndrome? According to the Mayo Clinic, sick sinus syndrome is a kind of heart rhythm disorder that causes heartbeats that are "too fast, too slow, interrupted by long pauses — or an alternating combination of these rhythm issues." The condition is "relatively uncommon." "The risk of developing it increases with age," the clinic notes. "Many people with sick sinus syndrome eventually need an implanted device called a pacemaker to keep the heart in a regular rhythm." 'Modern Family' cast share emotions of last script reading: 'I was sobbing' Bowen previously discussed the condition in a 2011 interview with WebMD. She said at the time that her pacemaker "serves as a monitor for me," adding that she is grateful "to live during a time when the technology exists to treat my condition." She also noted that she doesn't "hear or feel" the device. In fact, when Bowen's pacemaker was brought up on the "Inside of You" podcast, she said, "That's right. I forget about that all the time."

Precisio Biotix Therapeutics, Inc. (Precisio) Announces Dosing of a First Patient with ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection
Precisio Biotix Therapeutics, Inc. (Precisio) Announces Dosing of a First Patient with ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection

Yahoo

time2 hours ago

  • Yahoo

Precisio Biotix Therapeutics, Inc. (Precisio) Announces Dosing of a First Patient with ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection

DOVER, Del., July 03, 2025--(BUSINESS WIRE)--Precisio announced a first-in-man dosing of its staph lysin called ClyO (LYSG101) to a patient with a prosthetic joint infection that had not responded to other treatments. The FDA approved this treatment under a compassionate care IND filed by Mayo Clinic. The patient appears to have tolerated the treatment without any adverse events. It is too early to assess full efficacy, but this is certainly a significant step toward providing additional options to patients, particularly when traditional treatments have failed. Dr. Raymond Schuch, VP, Director of US Operations, notes, "Our sole company focus is the systematic engineering of native lysins and generation of drug-like, optimized and engineered lysins vs. antimicrobial-resistant human pathogens that are associated with high unmet medical needs. Our team possesses unique experience of developing these lysins and transitioning lysins into clinical studies and into patients. To date, our efforts have focused on respiratory, skin, and vaginal infections. We are excited to add prosthetic joint infections to the portfolio of infections we think that we can effectively treat." Mark Engel, Founder and CEO of Precisio said, "We are a platforms plus products company. The key to developing best-in-world lysins is that we use multiple self-developed high-tech proprietary tools. These include tools in bioinformatics, machine-learning, and AI (Zeus™-LysiThru™). We are now at a point where we think we can develop lysin products against many infections including those resistant to standard antibiotics. This patient at Mayo Clinic is the first of what we hope are many examples that we announce in the coming months. Doctors around the globe are anxious to start using our treatments on a compassionate basis since large numbers of patients are not responding to existing treatments." Dr. Assaf Raz, VP of Research and Development noted: "Drug-resistant infections are a pressing global health issue, causing at least 700,000 deaths each year. Without decisive action, this number could rise to 10 million annually by 2050, according to the UN Ad hoc Interagency Coordinating Group on Antimicrobial Resistance. Our research team is dedicated to developing new lysin therapeutics for large areas of need that bypass antibiotic resistance. We are highly encouraged that our technologies allow us to rapidly create effective solutions for multidrug-resistant pathogens, combating resistant infections and improving patient outcomes." Mr. Engel summarizes that, "The engineered lysins we are developing will have a tremendous impact as additional tool for treating and preventing infections. We think that our lysins will be effective against both gram-positive and gram-negative bacteria. Because we are so efficient in developing them, we will be able to produce our lysins in highly stable formulations with low cost-of-goods, thereby making them available to both developed markets and in the LMIC markets. This presents an opportunity to dramatically change health outcomes around the globe. We are now seeking both strategic and financial support to move forward more rapidly. Our team is highly motivated since we know that every day wasted means lives lost." About Lysins: Lysins are members of a promising new class of antimicrobials - direct lytic agents. Unlike traditional antibiotics, lysins actively hydrolyze the bacterial cell wall, causing extremely rapid lysis and cell death. Due to this unique mechanism of action, lysins are targeted to specific pathogens, can effectively degrade biofilms, and are effective against bacteria resistant to traditional antibiotics. Critically, unlike traditional antibiotics, they do not cause bacterial resistance. About Precisio Biotix Therapeutics Inc. ( Precisio is a US clinical stage biotech company creating lower-cost novel precision engineered biological antibacterials, with an initial focus on respiratory, skin, lung, and prosthetic joint infections. Precisio is a platform-plus-product company (Rx and consumer). The Company has additional R&D operations in India, China, and the UK. Management has had multiple previous successful exits and currently seeks strategic partners for all aspects of the business. Recent news includes (1) a grant award from the Gates Foundation for the development of lysins to treat Bacterial Vaginosis and (2) regulatory approval of a topical Lysin in the EU. View source version on Contacts Aileen Shen, Director of Investor Relations, shencj@ or Daniela Wambold, Corporate Partners, dwambold@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Giorgio Armani x Kith Go Global for Second Collaborative Release
Giorgio Armani x Kith Go Global for Second Collaborative Release

Hypebeast

time16 hours ago

  • Hypebeast

Giorgio Armani x Kith Go Global for Second Collaborative Release

Summary Back for a second time,Giorgio ArmaniandKithare reconnecting to refine their clean-cut collaborative language in an elegant new estate-inspired collection. Meaning 'summer' in Italian and 'property' in English, the 'estate' ethos is woven through the pair's sophomore selection of menswear and, for the first time, womenswear as well, which encapsulates the energy of a romantic, warm-weather getaway. Arriving a little under a year after the pair's debut collaboration, which was released back in August of 2024, the latest endeavor from Armani's legacy label and theRonnie Fieg-founded imprint draws inspiration from four key destinations: Malibu, The Hamptons, Forte Dei Marmi, and Porto Cervo. This collection continues to highlight the pair's perfected craftsmanship, exemplified across double-breasted blazers, bomber jackets and new shirting silhouettes, which land alongside seasonal accessories including sunglasses, bandanas, bags and belts. Take a closer look at the second Giorgio Armani x Kith collection in the lookbook above. In honor of the collaboration, the brands are hosting a series of special activations in Malibu, The Hamptons, Forte Dei Marmi, and Porto Cervo; early releases will go down at Kith Malibu on July 4, at the Giorgio Armani and Kith Hamptons House on July 5, and at the Topping Rose Hotel in Bridgehampton, New York at the Topping Rose Hotel on July 6. The global launch goes live via Giorgio Armani and Kith retailers on July 10.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store